Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London ...Middle East

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have...

Hence then, the article about hansa biopharma presents positive outcomes of five year follow up study of imlifidase in kidney transplantation at esot congress 2025 in london was published today ( Monday 30/06/2025 - 09:21 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London )

Also on site :

• One person in critical condition following two-vehicle collision on SR-126 at Boosey Road
• Kentucky congressman announces death of longtime staffer, campaign manager
• Supermarket timings for Boxing Day and New Year revealed for Asda, Tesco, Sainsbury’s, Aldi, Lidl and more